Best Neurology Companies in China
The 60 best Neurology companies in China in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Sironax.
China's neurology sector has real money behind it. Sixty companies tracked, $795M in disclosed funding, and no unicorns yet — which tells you the opportunity's still wide open. Sironax leads the pack at $200M raised, followed by Argo Biopharma at $104M and SciNeuro at $100M. That top tier alone accounts for over half the sector's total capital, and investors like Qiming Venture Partners and Arch Venture Partners keep showing up on cap tables. The global neurology market sits at roughly $112.5B in 2025, forecast to reach $180.2B by 2032 at a 6.9% CAGR, with an aging population and rising neurological disorder prevalence doing most of the driving.
What's interesting to me is where the scientific conversation is moving right now. Coverage is flat overall, but the hot themes — cognitive aging, post-concussion syndrome, chronic traumatic encephalopathy — signal where the next funding wave is likely to form. Stress-induced neuroinflammation is getting serious clinical attention this quarter, and epilepsy care advocacy is raising the public health profile of the category broadly. If you're mapping where China's neurology capital flows next, watch the cognitive aging pipeline and whoever's building around genetic research infrastructure.
Our analysis of 50 Neurology companies
$7.4b in tracked funding; 74% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
Ranked: Best Neurology companies in China
| # | Company | Disclosed funding | Last round | Stage | Founded | Founder | Employees | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Achieva Medical åŠ å¥‡ç”Ÿç‰©ç§‘æŠ€(上海)有é™å…¬å¸ is a medical devices company based out of… | — | — | Acquired | 2003 | Wang Chen CEO | 26 | — | — |
| 2 | AOBO medical device Devices for neurological disorders | — | — | Unfunded | 1996 | Sun ZuoDong Founder | — | — | — |
| 3 | Beijing Zhuokai Biotechnology Developer of drugs for the treatment of neurogenetic disorders | — | — | Funding Raised | 2001 | Wang Jian Co-Founder | — | — | — |
| 4 | Guangzhou Heng Nuo Kang Pharmaceutical Technology Developer of drugs for central nervous system monitoring | — | — | Funding Raised | 2013 | — | 85 | — | — |
| 5 | Hangzhou Jialiang Medical Technology Developer of devices for the treatment of epilepsy and other neurological diseases | — | — | Funding Raised | 2020 | Cao Peng CEO | — | — | — |
| 6 | Hemogen Developer of therapeutics for treating hemoglobin diseases | — | — | Unfunded | 2018 | Chao Liu CEO | — | — | — |
| 7 | iCamumo Developer of cell therapies for multiple diseases | — | — | Funding Raised | 2021 | Liu Xiaodong Founder | 80 | — | 2 job openings |
| 8 | Jinho Robot Rehabilitation robot systems for gait and balance for patients with neurological disorders | — | — | Unfunded | 2012 | Gu Jie CEO | — | — | — |
Top 12 Neurology companies in China
#1
Series A · Shanghai, Shanghai · founded 2020 · 22 employees$100Mraised▾
Developer of therapeutic solutions for the treatment of central nervous system disorders.
- Dec 2025Series A$53M
- Nov 2025Grant (prize money)$5M
- Dec 2020Series A$100M
#2
Series B · Wuhan, Hubei · founded 2017$40Mraised▾
Developer of cell therapies to treat neurological and ophthalmological diseases. The company focuses on the development of a new generation of chemically induced cell therapy products, for untreatable diseases, such as Parkinson's disease and blindness. The company's product pipeline includes NN001 and NN002 for neurological disorders, NS001, and NS001 for diabetic neuropathy and optic neuropathy.
- Sep 2025Series B$40M
- Aug 2021Series A—
- Jul 2020Seed—
- Jan 2019Seed—
#3
Series B · Minhang, Shanghai · founded 2021 · 100 employees$41.7Mraised▾
Developer of stem-cell therapies to treat neurodegenerative diseases. By using gene-editing technology, the company has engineered a pluripotent stem cell platform to develop therapeutics for degenerative diseases such as Parkinson's disease.
- Oct 2024Series B$14M
- Apr 2023Series A—
- Nov 2022Series A$27.7M
- Jan 2022Seed—
#4
Series A · Shanghai, Shanghai · founded 2021$103.8Mraised▾
Developer of oligonucleotide therapeutics for various diseases. The company specializes in siRNA drug discovery and development, utilizing siRNA platform technology and RADS to offer a pipeline of therapeutics for cardiovascular, rare diseases, CNS diseases, viral hepatitis, metabolic diseases, and more.
- Nov 2023Series A$41M
- Mar 2022Seed$62.8M
#5
Series C · Shanghai, Shanghai · founded 2015 · 118 employees$83Mraised▾
Drug Farm is a developer of a novel treatment for metabolic diseases. The company uses AI-directed medicinal chemistry to develop small molecule drugs against new targets. The product pipeline includes DF-006 for hepatitis-B, DF-007 for fatty liver disease, DF-008 for Cancer, and DF-003 for rare blindness.
- May 2023Series C$27M
- Feb 2021Series A$56M
#6
Series B · Changping District, Beijing · founded 2017$200Mraised▾
Developer of drugs for inflammatory and neurodegenerative diseases. The company is focusing on the development of small molecular compounds for targeting cell death signaling pathways. The company has a portfolio of drugs for inflammatory bowel disease, acute kidney injury, Alzheimer's, and multiple sclerosis.
- Aug 2022Series B$200M
#7
Series D · Suzhou, Jiangsu · founded 2011 · 29 employees$62.6Mraised▾
Developer of a portfolio of Neuromodulation devices. The company’s products include a deep brain stimulation system that includes implantable neuro-stimulator, extensions, patient controllers, accessories, leads, clinician programmers, and test neuro-stimulator. It also develops spinal cord stimulation and sacral nerve stimulation systems. Its deep brain stimulators have applications in the treatment of Parkinson's disease, Movement disorders, and Degenerative brain diseases, and its spinal cord and sacral nerve stimulators have applications in neuropathic pain management.
- Feb 2022Series D$47.3M
- Apr 2021Series D$15.4M
#8
Series A · Sichuan, Gansu Sheng$29.6Mraised▾
Developer of rAAV gene therapies for the treatment of multiple diseases
#9
Series D · Beijing, Beijing Shi · founded 2003 · 1 employees$13.9Mraised▾
Huake Precision provides neurosurgery robots. The company offers 3D visualization of intracranial blood vessels, correction of intraoperative brain drift where the intracranial electrodes are placed inside the brain. The company transmits brain wave signal receiving device for physicians to identify areas with abnormal inter-seizure function and epileptic focus. Its products offering are cortical electrode, depth electrode, and huake hengseng sphenoid electrode among others. It is used for epilepsy surgery, Parkinson's disease and DBS surgery, intracranial tumor surgery, intracranial hemorrhage, and stereotactic puncture and drainage.
- Jul 2023Series D$13.9M
- Dec 2022Series D—
- Dec 2020Series B—
- Jul 2020Series B—
#10
Series A · Suzhou, Jiangsu · founded 2018 · 9 employees$25Mraised▾
Developer of drugs for neurological disorders. It offers pipeline candidates which include FB-1071 for amyotrophic lateral sclerosis, FB-1005 for stroke, FB1001 for glaucoma, FB1003 for pain, and FB1004 for Alzheimer's disease.
- Dec 2022Series A$14M
- Feb 2021Series A—
#11
Series A · Shanghai, Shanghai · founded 2018 · 5 employees$60Mraised▾
BioShin is a developer of therapeutic solutions for treating neurodegenerative diseases. It has developed a BHV3000-301 product that is in phase 3 clinical trials helps in treating migraine pain. Its product BHV-0223 use for the treatment of amyotrophic lateral sclerosis diseases. Other products including TRORILUZOLE is a prodrug and new compound that regulates glutamate & increases the uptake of glutamate by increasing the expression of excitatory amino acid transporters located on glial cells. It affects the pathophysiological process of many diseases, including amyotrophic lateral sclerosis (ALS), spinocerebellar ataxia (SCA), Alzheimer's disease (AD), anxiety, depression, Obsessive-compulsive disorder (OCD), chronic pain, and various cancers.
- Sep 2020Series A$60M
#12
Series C · Pudong, Shanghai · founded 2018 · 150 employees$18.5Mraised▾
Developer of gene therapies for the treatment of multiple disease conditions. The company is focusing on gene therapy drugs such as gene replacement and gene editing for rare single-gene genetic diseases. The company's pipeline includes HG-001, HG-202, HG-004, HG-203 for neurodegenerative diseases, visual impairment, and hearing impairment.
- May 2022Series C—
- Dec 2019Series A$14.2M
- Nov 2018Seed$4.3M
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Neurology coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
How research on Neuroscience & Neurotech is moving in China
A read on the academic research around Neuroscience & Neurotech — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 2,183 China-affiliated papers.
- Capital Medical University322
- Shanghai Jiao Tong University174
- Beijing Tian Tan Hospital172
- Chinese Academy of Sciences152
- Ruijin Hospital145
- Deep brain stimulation17→110
- Stimulation12→79
- Neurostimulation4→29
- Neuroprosthetics2→25
- Brain–computer interface4→22
- Deep brain stimulation175→469
- Stimulation87→215
- Neuromodulation6→114
- Parkinson's disease70→166
- Subthalamic nucleus90→170
- Deep brain stimulation41→79
- Neuromodulation1→31
- Transcranial magnetic stimulation1→18
- Parkinson's disease17→32
- Neuroimaging1→13
Where neurotech is researched across China
Location clusters by institution affiliation — each city's volume, stance tone, and a quick read on its hot topic, what's advancing, the opening opportunity, and the main concern.
Who's filing neurotech patents in China
China neurotech patent filing is accelerating — 90 filings from 36 assignees (2016–2025), led by Wuhan Neuracom TECH Development, Sceneray, Shenzhen INST Of ADV TECH CAS; annual filings 2→24.
- Wuhan Neuracom TECH Development16
- Sceneray10
- Shenzhen INST Of ADV TECH CAS7
- South China Brain Computer Inter6
- UNIV Zhejiang5
- UNIV Tsinghua5
- UNIV Tianjin4
- Huawei TECH4
Common questions
Rohit lives in the feed. He covers what's moving right now — the funding rounds, launches and shifts breaking across the trade press — and ties them back to where the sector is heading.